PHENTrials.com
PHENTrials.com provides easy access to clinical trials for all prostate cancer diagnoses. Patients can identify and review trials that may be appropriate for them.
“Increasing Participation in Prostate Cancer Clinical Trials to Save Lives.”
PHENTrials.com
PHENTrials.com provides easy access to clinical trials for all prostate cancer diagnoses. Patients can identify and review trials that may be appropriate for them.
Increasing Participation in Prostate Cancer Clinical Trials to Save Lives
Find Your Trial
PHEN’s Find Your Trial (FYT) search tool connects patients with prostate cancer clinical trials based on a patient’s diagnosis and where they are located.
Prostate Cancer Diagnoses
Low Risk
Patients with an initial diagnosis of PSA less than 10, Gleason 6/Grade Group 1. Cancer involves one half of one side of the prostate or less.
Intermediate Risk
(Favorable): Patients with an initial diagnosis that includes one of the following: Gleason 7/Grade Group 2, PSA 10-20, or cancer involves more than one-half of one side of the prostate or involves both sides of the prostate
(Unfavorable): Patients with an initial diagnosis of Gleason 7/Grade Group 3 or that includes 2 or 3 of the following: Gleason 7/Grade Group 2, PSA 10-20, cancer involves more than one-half of one side of the prostate or involves both sides of the prostate.
High Risk
Patients with an initial diagnosis that includes one of the following: PSA more than 20, Gleason 8-9/Grade Group 4-5, tumor has spread a little outside the prostate.
Cancer Recurrence
For patients with a PSA biochemical recurrence after prostate removal through surgery or after radiation.
Non-Metastatic Castration Resistant
NMCRPC is castration-resistant prostate cancer without signs of distant metastases.
Metastatic Castration Sensitive
For patients with metastatic prostate cancer that still responds to hormone (androgen deprivation) treatment.
Metastatic Castration Resistant
MCRPC is castration-resistant prostate cancer with distant metastases.
Neuroendocrine
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise in new patients or those previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance.
Patient Summaries
Our Partners
For Partnership Interest
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.